betamethasone dipropionate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
prednisone and prednisolone derivatives 353 5593-20-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • betamethasone dipropionate
  • diproderm
  • diprosone
A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)
  • Molecular weight: 504.60
  • Formula: C28H37FO7
  • CLOGP: 3.92
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 1
  • TPSA: 106.97
  • ALOGS: -5.04
  • ROTB: 8
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.06 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.297 High 0.88
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.002 High 0.88
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 76.560 10^-6 cm/s High 0.88
dh-clint Dog hepatocyte intrinsic clearance 93.541 uL/min/10^6 cells High 0.88
dppb Dog plasma protein binding (% unbound) 3.780 % High 0.88
fcs-ppb Fetal calf serum protein binding (% unbound) 4.920 % High 0.88
herg hERG pIC50 4.737 pIC50 High 0.88
hh-clint Human hepatocyte intrinsic clearance 142.889 uL/min/10^6 cells High 0.88
hlm-clint Human liver microsomal intrinsic clearance 250.035 uL/min/mg protein High 0.88
hppb Human plasma protein binding (% unbound) 4.300 % High 0.88
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.600 Moderate 0.65
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 4.775 High 0.88
mh-clint Mouse hepatocyte intrinsic clearance 189.671 High 0.88
mppb Mouse plasma protein binding (% unbound) 3.190 High 0.88
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 13.900 High 0.88
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 0.80
pppb Pig plasma protein binding (% unbound) 8.220 % High 0.88
rat-kpuu-brain Rat brain Kpuu 0.207 % Moderate 0.65
rh-clint Rat hepatocyte intrinsic clearance 198.153 uL/min/10^6 cells High 0.88
rh-fuinc Rat hepatocyte fraction unbound in incubation 27.820 % High 0.88
rppb Rat plasma protein binding (% unbound) 2.910 % High 0.88
solubility-dd Solubility at pH 7.4 in DMSO 23.174 uM High 0.88

Approvals:

DateAgencyCompanyOrphan
Jan. 29, 1975 FDA SCHERING

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 519.74 12.70 217 17872 37753 90572605
Psoriasis 172.09 12.70 178 17911 147576 90462782
Chronic sinusitis 150.81 12.70 80 18009 23722 90586636
Protothecosis 143.09 12.70 30 18059 441 90609917
Vaginal flatulence 135.94 12.70 61 18028 12577 90597781
Paraesthesia oral 134.66 12.70 82 18007 31577 90578781
Female genital tract fistula 133.20 12.70 67 18022 17801 90592557
Dermatitis atopic 132.28 12.70 73 18016 23399 90586959
Drug ineffective 131.28 12.70 583 17506 1383715 89226643
Procedural pain 130.70 12.70 82 18007 33278 90577080
Radiculopathy 125.21 12.70 65 18024 18440 90591918
Proctitis 124.97 12.70 61 18028 15198 90595160
Vaginal discharge 113.72 12.70 62 18027 19402 90590956
Incorrect route of product administration 104.15 12.70 84 18005 50542 90559816
Oral candidiasis 97.61 12.70 70 18019 35385 90574973
Skin fissures 88.74 12.70 54 18035 20755 90589603
Frequent bowel movements 79.90 12.70 76 18013 56859 90553499
Colitis ulcerative 74.40 12.70 75 18014 60191 90550167
Libido increased 73.75 12.70 23 18066 1721 90608637
Product use in unapproved indication 72.14 12.70 187 17902 336049 90274309
Erythema 70.61 12.70 147 17942 229099 90381259
Systemic candida 69.96 12.70 29 18060 4930 90605428
Soft tissue injury 69.64 12.70 23 18066 2069 90608289
Post-traumatic neck syndrome 69.34 12.70 24 18065 2490 90607868
Eczema 69.34 12.70 68 18021 52802 90557556
Rectal haemorrhage 69.27 12.70 84 18005 82660 90527698
Hostility 67.76 12.70 23 18066 2250 90608108
Haematochezia 62.66 12.70 74 18015 70839 90539519
Sternal fracture 62.39 12.70 23 18066 2864 90607494
Therapeutic product effect incomplete 60.46 12.70 125 17964 193771 90416587
Dyspepsia 59.75 12.70 126 17963 198034 90412324
Colitis 56.91 12.70 70 18019 69872 90540486
Steroid withdrawal syndrome 55.81 12.70 15 18074 661 90609697
Staphylococcal bacteraemia 55.63 12.70 28 18061 7441 90602917
Overlap syndrome 54.89 12.70 29 18060 8519 90601839
Streptococcal sepsis 54.10 12.70 22 18067 3562 90606796
Skin exfoliation 47.41 12.70 63 18026 67850 90542508
Pseudomonal sepsis 47.01 12.70 21 18068 4281 90606077
Candida infection 46.89 12.70 45 18044 34012 90576346
Nail bed inflammation 45.10 12.70 16 18073 1785 90608573
Nasal mucosal disorder 44.62 12.70 16 18073 1841 90608517
Anhidrosis 40.17 12.70 9 18080 183 90610175
Paronychia 39.95 12.70 23 18066 7983 90602375
Dry skin 38.96 12.70 66 18023 88007 90522351
Concussion 37.83 12.70 25 18064 11066 90599292
Weight decreased 37.78 12.70 163 17926 379747 90230611
Vascular device infection 36.14 12.70 25 18064 11927 90598431
Bacteraemia 35.60 12.70 32 18057 22268 90588090
Sleep disorder due to a general medical condition 35.14 12.70 44 18045 44694 90565664
Varicose vein 33.79 12.70 20 18069 7307 90603051
Pruritus 33.28 12.70 203 17886 541322 90069036
Middle insomnia 32.76 12.70 27 18062 16724 90593634
Death 31.40 12.70 27 18062 456524 90153834
Personality disorder 30.69 12.70 23 18066 12421 90597937
Pemphigus 28.26 12.70 15 18074 326849 90283509
Poor quality sleep 27.34 12.70 29 18060 24664 90585694
Skin burning sensation 27.16 12.70 26 18063 19585 90590773
Portal vein cavernous transformation 26.97 12.70 6 18083 118 90610240
Systemic lupus erythematosus 26.63 12.70 20 18069 361876 90248482
Skin atrophy 25.25 12.70 15 18074 5514 90604844
Toxicity to various agents 25.19 12.70 13 18076 287833 90322525
Metastases to central nervous system 23.81 12.70 23 18066 17519 90592839
Skin plaque 23.63 12.70 18 18071 9957 90600401
Blood pressure inadequately controlled 23.61 12.70 15 18074 6209 90604149
Drug hypersensitivity 23.60 12.70 35 18054 463574 90146784
Drug interaction 23.44 12.70 13 18076 276440 90333918
Metastases to lymph nodes 23.19 12.70 19 18070 11670 90598688
Nightmare 23.15 12.70 25 18064 21700 90588658
Hypotension 22.65 12.70 19 18070 325378 90284980
Lichenification 22.60 12.70 7 18082 512 90609846
Theft 22.35 12.70 5 18084 101 90610257
Guttate psoriasis 21.70 12.70 7 18082 584 90609774
Nail psoriasis 20.32 12.70 7 18082 716 90609642
Rheumatoid arthritis 19.82 12.70 26 18063 362588 90247770
Dyspnoea 19.56 12.70 100 17989 880855 89729503
Off label use 19.43 12.70 318 17771 1101934 89508424
Rib fracture 19.18 12.70 25 18064 26410 90583948
Central obesity 19.17 12.70 8 18081 1382 90608976
Swelling 19.10 12.70 34 18055 419024 90191334
Bacterial vulvovaginitis 19.03 12.70 7 18082 866 90609492
Psoriatic arthropathy 18.97 12.70 93 17996 228242 90382116
Hypersensitivity 18.89 12.70 39 18050 454638 90155720
Movement disorder 18.85 12.70 26 18063 28993 90581365
Exercise tolerance decreased 18.72 12.70 14 18075 7537 90602821
Hand deformity 18.62 12.70 19 18070 296343 90314015
Bacillus infection 18.39 12.70 7 18082 952 90609406
Toxic neuropathy 18.14 12.70 6 18083 542 90609816
Cutaneous T-cell lymphoma 17.99 12.70 8 18081 1612 90608746
Muscle twitching 17.73 12.70 23 18066 24179 90586179
Irritability 17.48 12.70 28 18061 35634 90574724
Anaemia macrocytic 17.30 12.70 11 18078 4561 90605797
Drug intolerance 17.26 12.70 40 18049 447551 90162807
Therapeutic product effect delayed 16.95 12.70 10 18079 3631 90606727
Brain oedema 16.78 12.70 19 18070 17366 90592992
Tachycardia paroxysmal 16.66 12.70 5 18084 329 90610029
Confusional state 16.14 12.70 33 18056 386172 90224186
Total bile acids increased 16.09 12.70 4 18085 129 90610229
Synovitis 15.71 12.70 26 18063 329726 90280632
Intraocular haematoma 15.66 12.70 3 18086 27 90610331
Tendon injury 15.48 12.70 8 18081 2245 90608113
Inappropriate schedule of product administration 15.38 12.70 65 18024 149868 90460490
Refractory anaemia with an excess of blasts 15.27 12.70 5 18084 438 90609920
Bacterial infection 15.22 12.70 21 18068 23423 90586935
Seizure 14.73 12.70 6 18083 152623 90457735
Lower respiratory tract infection 14.71 12.70 17 18072 250642 90359716
Pemphigoid 14.50 12.70 13 18076 9013 90601345
Madarosis 14.40 12.70 9 18080 3620 90606738
Furuncle 14.39 12.70 12 18077 7549 90602809
Weaning failure 14.35 12.70 5 18084 529 90609829
Body temperature increased 14.11 12.70 29 18060 44681 90565677
Freezing phenomenon 14.10 12.70 7 18082 1805 90608553
Skin lesion 13.94 12.70 26 18063 37339 90573019
Arthropathy 13.90 12.70 33 18056 366209 90244149
Toxic epidermal necrolysis 13.88 12.70 24 18065 32504 90577854
Glossodynia 13.87 12.70 27 18062 321752 90288606
Skin swelling 13.65 12.70 11 18078 6603 90603755
Subretinal haematoma 13.58 12.70 3 18086 57 90610301
Restlessness 13.50 12.70 25 18064 35695 90574663
Cushing's syndrome 13.50 12.70 5 18084 631 90609727
Skin bacterial infection 13.38 12.70 5 18084 646 90609712
Cell marker increased 13.10 12.70 4 18085 279 90610079
Dysgeusia 13.09 12.70 31 18058 52529 90557829
Thyroid gland injury 12.76 12.70 3 18086 76 90610282

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug eruption 250.42 19.23 135 15187 22940 42583073
Respiratory symptom 191.50 19.23 89 15233 11017 42594996
Psoriasis 184.10 19.23 147 15175 48457 42557556
Pulmonary vasculitis 166.10 19.23 68 15254 6198 42599815
Hepatic function abnormal 164.11 19.23 141 15181 51426 42554587
Neuritis 156.39 19.23 65 15257 6155 42599858
Sleep disorder due to a general medical condition 137.81 19.23 83 15239 17370 42588643
Stomatitis 137.01 19.23 126 15196 50203 42555810
Eosinophilic granulomatosis with polyangiitis 132.88 19.23 64 15258 8574 42597439
Pain in extremity 130.97 19.23 211 15111 150393 42455620
Conjunctivitis allergic 129.43 19.23 56 15266 5855 42600158
Myasthenia gravis 128.07 19.23 77 15245 16060 42589953
Neurological symptom 126.94 19.23 65 15257 9926 42596087
Mite allergy 121.04 19.23 51 15271 4995 42601018
Mycotic allergy 119.22 19.23 50 15272 4841 42601172
Dust allergy 118.34 19.23 51 15271 5281 42600732
Pulmonary alveolar haemorrhage 115.77 19.23 70 15252 14746 42591267
Hyperphosphataemia 113.53 19.23 66 15256 12938 42593075
Spirometry abnormal 113.48 19.23 49 15273 5097 42600916
Hypersensitivity 112.04 19.23 134 15188 72236 42533777
Urticaria 111.21 19.23 135 15187 73901 42532112
Full blood count abnormal 108.03 19.23 88 15234 29788 42576225
Appendicolith 103.66 19.23 63 15259 13393 42592620
Thrombosis 103.01 19.23 125 15197 68386 42537627
Incorrect route of product administration 101.64 19.23 78 15244 24227 42581786
Sleep disorder 98.35 19.23 103 15219 47992 42558021
Normochromic normocytic anaemia 98.34 19.23 53 15269 8978 42597035
Lung disorder 96.86 19.23 102 15220 47821 42558192
Analgesic therapy 96.30 19.23 47 15275 6477 42599536
Epistaxis 95.73 19.23 119 15203 66707 42539306
Vasculitis 94.89 19.23 67 15255 18327 42587686
Drug therapy 94.29 19.23 46 15276 6334 42599679
Sleep disorder therapy 93.84 19.23 47 15275 6847 42599166
Blood phosphorus increased 92.28 19.23 57 15265 12468 42593545
Pulmonary fibrosis 91.04 19.23 76 15246 26605 42579408
Asthma 89.30 19.23 111 15211 62203 42543810
Hypophosphataemia 89.30 19.23 68 15254 20877 42585136
Total lung capacity abnormal 87.26 19.23 39 15283 4404 42601609
Appendicitis 85.85 19.23 66 15256 20547 42585466
Obstructive airways disorder 85.46 19.23 71 15251 24688 42581325
Neuralgia 85.33 19.23 72 15250 25575 42580438
Muscle spasms 83.61 19.23 127 15195 85917 42520096
Antineutrophil cytoplasmic antibody positive 81.54 19.23 37 15285 4328 42601685
Anticoagulant therapy 80.19 19.23 37 15285 4498 42601515
Nodule 79.77 19.23 52 15270 12482 42593531
Hypothyroidism 78.96 19.23 76 15246 32008 42574005
Antacid therapy 78.80 19.23 37 15285 4680 42601333
Blood uric acid increased 78.73 19.23 56 15266 15491 42590522
Forced expiratory volume decreased 75.40 19.23 42 15280 7588 42598425
Arteriosclerosis coronary artery 73.86 19.23 58 15264 18619 42587394
Activated partial thromboplastin time prolonged 73.05 19.23 54 15268 15849 42590164
Therapeutic product effect incomplete 72.17 19.23 107 15215 70832 42535181
Toxicity to various agents 69.64 19.23 3 15319 229133 42376880
Congenital hiatus hernia 69.36 19.23 37 15285 6137 42599876
Pulmonary embolism 68.57 19.23 140 15182 119472 42486541
Arteriosclerosis 67.14 19.23 54 15268 17935 42588078
Bronchopulmonary aspergillosis allergic 64.51 19.23 32 15290 4566 42601447
Bacterial infection 62.93 19.23 63 15259 27816 42578197
Stress 62.10 19.23 78 15244 44134 42561879
Blood calcium increased 61.07 19.23 38 15284 8416 42597597
Condition aggravated 56.03 19.23 213 15109 260541 42345472
Blood cholesterol increased 55.93 19.23 58 15264 26683 42579330
Capillaritis 55.04 19.23 23 15299 2205 42603808
Iron deficiency 54.06 19.23 39 15283 11022 42594991
Ventricular fibrillation 53.64 19.23 60 15262 30063 42575950
Haemoptysis 53.32 19.23 74 15248 46093 42559920
Ulcer 52.31 19.23 45 15277 16396 42589617
End stage renal disease 52.03 19.23 45 15277 16513 42589500
Blood test abnormal 50.85 19.23 40 15282 12866 42593147
Cardiogenic shock 50.24 19.23 63 15259 35577 42570436
Skin exfoliation 50.09 19.23 68 15254 41485 42564528
Acute kidney injury 49.57 19.23 36 15286 367301 42238712
Dermatitis atopic 47.92 19.23 38 15284 12366 42593647
Diabetes mellitus 47.78 19.23 81 15241 60006 42546007
Hyperlipidaemia 47.41 19.23 48 15274 21468 42584545
Wheezing 46.43 19.23 76 15246 54705 42551308
Bacteroides infection 45.40 19.23 21 15301 2566 42603447
Drug interaction 44.80 19.23 20 15302 266979 42339034
Troponin increased 44.72 19.23 44 15278 19018 42586995
Gout 43.43 19.23 52 15270 28003 42578010
Intentional product misuse 42.19 19.23 78 15244 61822 42544191
Onychoclasis 41.84 19.23 20 15302 2632 42603381
Pleuritic pain 39.34 19.23 27 15295 7050 42598963
Dry mouth 38.87 19.23 59 15263 39820 42566193
Psoriatic arthropathy 38.19 19.23 46 15276 24921 42581092
Loss of personal independence in daily activities 38.07 19.23 66 15256 49750 42556263
Hypotension 36.36 19.23 24 15298 257607 42348406
Chronic obstructive pulmonary disease 36.26 19.23 74 15248 63040 42542973
Ascites 34.40 19.23 68 15254 56610 42549403
Micturition urgency 32.74 19.23 30 15292 11868 42594145
Multiple organ dysfunction syndrome 31.24 19.23 91 15231 96944 42509069
Febrile neutropenia 30.98 19.23 14 15308 185689 42420324
Abdominal distension 30.94 19.23 75 15247 71660 42534353
Palmoplantar pustulosis 30.47 19.23 10 15312 485 42605528
Hyponatraemia 29.69 19.23 92 15230 101370 42504643
Drug intolerance 28.40 19.23 78 15244 80346 42525667
Aortic stenosis 27.94 19.23 24 15298 8721 42597292
Drug ineffective 27.55 19.23 346 14976 629851 41976162
Aspiration 27.43 19.23 33 15289 17853 42588160
Drug abuse 27.11 19.23 3 15319 104768 42501245
Product use in unapproved indication 26.73 19.23 134 15188 184322 42421691
Pruritus 26.56 19.23 136 15186 188635 42417378
Secondary hypogonadism 25.95 19.23 10 15312 776 42605237
Total lung capacity decreased 25.66 19.23 16 15306 3554 42602459
Seizure 25.52 19.23 6 15316 120555 42485458
Drug hypersensitivity 25.35 19.23 86 15236 99303 42506710
Inflammatory pain 25.17 19.23 9 15313 566 42605447
Thrombocytopenia 25.15 19.23 19 15303 190260 42415753
Breath sounds abnormal 24.87 19.23 26 15296 12067 42593946
Fall 24.46 19.23 29 15293 234491 42371522
Cardiovascular disorder 24.43 19.23 27 15295 13338 42592675
Anhidrosis 24.37 19.23 7 15315 216 42605797
Cardiac arrest 24.03 19.23 5 15317 109315 42496698
Joint injury 24.03 19.23 28 15294 14648 42591365
Hypercholesterolaemia 23.56 19.23 26 15296 12823 42593190
Productive cough 23.40 19.23 55 15267 51512 42554501
Hypoxia 22.98 19.23 66 15256 69720 42536293
Erythrodermic psoriasis 22.83 19.23 10 15312 1076 42604937
Madarosis 22.45 19.23 8 15314 498 42605515
Polydipsia 22.33 19.23 16 15306 4472 42601541
Diarrhoea 22.20 19.23 88 15234 460761 42145252
Neutropenia 21.50 19.23 24 15298 199407 42406606
Pancytopenia 21.04 19.23 8 15314 117735 42488278
Benign prostatic hyperplasia 20.30 19.23 31 15291 21021 42584992

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 301.76 12.97 276 30824 139717 110418482
Drug eruption 207.58 12.97 149 30951 53510 110504689
Incorrect route of product administration 196.91 12.97 155 30945 63906 110494293
Respiratory symptom 193.16 12.97 91 31009 14854 110543345
Pulmonary vasculitis 182.82 12.97 69 31031 6491 110551708
Neuritis 167.77 12.97 67 31033 7332 110550867
Hepatic function abnormal 163.56 12.97 161 30939 89134 110469065
Sleep disorder due to a general medical condition 145.06 12.97 119 30981 51993 110506206
Conjunctivitis allergic 140.80 12.97 58 31042 6873 110551326
Macular degeneration 139.99 12.97 83 31017 21576 110536623
Eosinophilic granulomatosis with polyangiitis 137.88 12.97 65 31035 10621 110547578
Myasthenia gravis 130.13 12.97 79 31021 21432 110536767
Mite allergy 129.67 12.97 52 31048 5751 110552448
Mycotic allergy 128.38 12.97 52 31048 5902 110552297
Dust allergy 127.98 12.97 52 31048 5949 110552250
Protothecosis 127.82 12.97 30 31070 527 110557672
Spirometry abnormal 125.41 12.97 50 31050 5447 110552752
Dermatitis atopic 124.95 12.97 82 31018 25459 110532740
Chronic sinusitis 118.99 12.97 79 31021 25005 110533194
Vaginal flatulence 118.31 12.97 61 31039 12083 110546116
Appendicolith 117.37 12.97 64 31036 14191 110544008
Neurological symptom 117.34 12.97 66 31034 15542 110542657
Hyperphosphataemia 117.04 12.97 67 31033 16314 110541885
Female genital tract fistula 116.52 12.97 67 31033 16452 110541747
Pulmonary alveolar haemorrhage 114.23 12.97 71 31029 20079 110538120
Analgesic therapy 105.48 12.97 48 31052 7236 110550963
Paraesthesia oral 104.57 12.97 82 31018 33589 110524610
Sleep disorder therapy 104.32 12.97 48 31052 7423 110550776
Drug therapy 102.29 12.97 47 31053 7244 110550955
Proctitis 101.96 12.97 62 31038 16865 110541334
Radiculopathy 101.76 12.97 65 31035 19271 110538928
Therapeutic product effect incomplete 99.16 12.97 204 30896 223601 110334598
Vaginal discharge 98.74 12.97 62 31038 17846 110540353
Total lung capacity abnormal 98.72 12.97 40 31060 4543 110553656
Procedural pain 98.51 12.97 81 31019 35484 110522715
Normochromic normocytic anaemia 97.58 12.97 55 31045 13002 110545197
Blood phosphorus increased 93.70 12.97 58 31042 16282 110541917
Thrombosis 93.33 12.97 133 30967 108529 110449670
Antineutrophil cytoplasmic antibody positive 88.15 12.97 38 31062 5038 110553161
Bacterial infection 87.99 12.97 85 31015 45951 110512248
Appendicitis 87.70 12.97 69 31031 28395 110529804
Toxicity to various agents 87.40 12.97 15 31085 480540 110077659
Anticoagulant therapy 82.94 12.97 37 31063 5324 110552875
Antacid therapy 82.14 12.97 37 31063 5447 110552752
Full blood count abnormal 80.91 12.97 89 31011 55963 110502236
Arteriosclerosis coronary artery 79.79 12.97 62 31038 25056 110533143
Hypophosphataemia 78.44 12.97 69 31031 33113 110525086
Congenital hiatus hernia 77.46 12.97 37 31063 6222 110551977
Neuralgia 77.04 12.97 81 31019 48397 110509802
Blood uric acid increased 76.91 12.97 57 31043 21472 110536727
Skin fissures 76.88 12.97 60 31040 24398 110533801
Arteriosclerosis 74.07 12.97 59 31041 24708 110533491
Product use in unapproved indication 73.45 12.97 284 30816 447093 110111106
Vasculitis 71.90 12.97 68 31032 35805 110522394
Skin exfoliation 70.47 12.97 104 30996 87547 110470652
Oral candidiasis 69.73 12.97 74 31026 44686 110513513
Activated partial thromboplastin time prolonged 68.43 12.97 54 31046 22314 110535885
Forced expiratory volume decreased 66.14 12.97 43 31057 13133 110545066
Hypothyroidism 65.21 12.97 91 31009 72808 110485391
Obstructive airways disorder 64.40 12.97 72 31028 46077 110512122
Pain in extremity 64.11 12.97 289 30811 486829 110071370
Epistaxis 63.88 12.97 124 30976 130248 110427951
Anhidrosis 63.04 12.97 16 31084 394 110557805
Drug interaction 62.97 12.97 31 31069 500152 110058047
Post-traumatic neck syndrome 60.57 12.97 24 31076 2571 110555628
Soft tissue injury 60.03 12.97 23 31077 2253 110555946
Capillaritis 58.48 12.97 23 31077 2416 110555783
Hypotension 58.02 12.97 38 31062 523811 110034388
Libido increased 57.59 12.97 23 31077 2516 110555683
Hostility 56.25 12.97 23 31077 2673 110555526
Stress 53.82 12.97 102 30998 105246 110452953
Bronchopulmonary aspergillosis allergic 53.68 12.97 32 31068 8394 110549805
Ventricular fibrillation 53.48 12.97 62 31038 41251 110516948
Iron deficiency 53.09 12.97 43 31057 18433 110539766
Eczema 52.75 12.97 82 31018 72211 110485988
Diabetes mellitus 51.73 12.97 97 31003 99284 110458915
Sternal fracture 51.66 12.97 23 31077 3293 110554906
End stage renal disease 51.45 12.97 45 31055 21428 110536771
Nodule 50.92 12.97 54 31046 32577 110525622
Drug ineffective 50.61 12.97 650 30450 1519890 109038309
Frequent bowel movements 49.36 12.97 79 31021 71311 110486888
Pulmonary embolism 48.95 12.97 152 30948 214322 110343877
Bacteroides infection 47.91 12.97 21 31079 2898 110555301
Erythema 46.93 12.97 184 30916 291263 110266936
Overlap syndrome 46.54 12.97 30 31070 9029 110549170
Blood calcium increased 45.64 12.97 39 31061 18001 110540198
Sleep disorder 45.53 12.97 141 30959 198503 110359696
Haemoptysis 45.33 12.97 76 31024 71278 110486921
Troponin increased 44.23 12.97 48 31052 29718 110528481
Gout 44.22 12.97 53 31047 36513 110521686
Streptococcal sepsis 42.38 12.97 23 31077 5049 110553150
Colitis ulcerative 42.13 12.97 77 31023 77286 110480913
Systemic candida 41.56 12.97 29 31071 9945 110548254
Lung disorder 41.44 12.97 128 30972 179919 110378280
Pulmonary fibrosis 40.49 12.97 89 31011 101953 110456246
Cardiogenic shock 40.39 12.97 64 31036 57274 110500925
Hyperlipidaemia 40.17 12.97 50 31050 35798 110522401
Staphylococcal bacteraemia 40.03 12.97 35 31065 16653 110541546
Onychoclasis 39.75 12.97 25 31075 7212 110550987
Asthma 39.46 12.97 157 30943 250134 110308065
Nasal mucosal disorder 39.07 12.97 16 31084 1867 110556332
Stomatitis 39.04 12.97 165 30935 270077 110288122
Urticaria 38.80 12.97 185 30915 318672 110239527
Acute kidney injury 38.76 12.97 75 31025 635355 109922844
Dry skin 38.39 12.97 90 31010 107563 110450636
Nail bed inflammation 37.91 12.97 16 31084 2014 110556185
Fall 36.13 12.97 72 31028 603410 109954789
Dyspepsia 35.24 12.97 126 30974 190839 110367360
Confusional state 34.43 12.97 49 31051 468631 110089568
Ulcer 34.41 12.97 51 31049 43065 110515134
Seizure 33.97 12.97 10 31090 221175 110337024
Palmoplantar pustulosis 33.49 12.97 12 31088 974 110557225
Madarosis 32.59 12.97 17 31083 3446 110554753
Pseudomonal sepsis 32.42 12.97 24 31076 9022 110549177
Paronychia 32.28 12.97 26 31074 11055 110547144
Blood test abnormal 32.27 12.97 40 31060 28514 110529685
Candida infection 31.65 12.97 52 31048 47957 110510242
Erythrodermic psoriasis 31.50 12.97 14 31086 1996 110556203
Muscle spasms 31.40 12.97 158 30942 277999 110280200
Haematochezia 31.24 12.97 87 31013 115437 110442762
Skin burning sensation 30.36 12.97 34 31066 21791 110536408
Cardiac arrest 30.02 12.97 9 31091 196744 110361455
Colitis 29.60 12.97 79 31021 102244 110455955
Concussion 29.30 12.97 25 31075 11513 110546686
Rectal haemorrhage 29.26 12.97 87 31013 119746 110438453
Pruritus 28.58 12.97 269 30831 581291 109976908
Varicose vein 28.50 12.97 20 31080 6920 110551279
Benign prostatic hyperplasia 28.13 12.97 30 31070 18204 110539995
Secondary hypogonadism 27.43 12.97 10 31090 853 110557346
Systemic lupus erythematosus 27.38 12.97 19 31081 254319 110303880
Chronic obstructive pulmonary disease 27.36 12.97 80 31020 109078 110449121
Condition aggravated 26.79 12.97 320 30780 734516 109823683
Micturition urgency 26.70 12.97 30 31070 19290 110538909
Rheumatoid arthritis 26.58 12.97 27 31073 299586 110258613
Steroid withdrawal syndrome 26.55 12.97 10 31090 935 110557264
Intentional product misuse 26.51 12.97 90 31010 132814 110425385
Ascites 26.19 12.97 71 31029 92737 110465462
Pemphigus 25.92 12.97 14 31086 214556 110343643
Pleuritic pain 25.69 12.97 27 31073 16113 110542086
Sepsis 25.21 12.97 168 30932 327178 110231021
Thrombocytopenia 25.09 12.97 37 31063 348848 110209351
Aortic stenosis 24.73 12.97 24 31076 13035 110545164
Portal vein cavernous transformation 24.29 12.97 6 31094 132 110558067
Psoriatic arthropathy 23.79 12.97 114 30986 196647 110361552
Middle insomnia 23.62 12.97 29 31071 20473 110537726
Vascular device infection 23.44 12.97 26 31074 16486 110541713
Arthropathy 23.21 12.97 28 31072 287494 110270705
Personality disorder 23.21 12.97 23 31077 12814 110545385
Lung opacity 23.17 12.97 22 31078 11630 110546569
Multiple organ dysfunction syndrome 22.96 12.97 94 31006 151616 110406583
Coma 22.96 12.97 3 31097 117866 110440333
Pemphigoid 22.91 12.97 28 31072 19679 110538520
Synovitis 22.87 12.97 26 31074 274066 110284133
Aspiration 22.78 12.97 35 31065 30498 110527701
Pain of skin 22.54 12.97 28 31072 20001 110538198
Overdose 21.98 12.97 20 31080 233774 110324425
Plantar fasciitis 21.65 12.97 15 31085 5086 110553113
Death 21.11 12.97 113 30987 698756 109859443
Incorrect product administration duration 20.46 12.97 27 31073 20471 110537728
Skin atrophy 20.40 12.97 16 31084 6548 110551651
Guttate psoriasis 19.83 12.97 7 31093 544 110557655
Male genital atrophy 19.45 12.97 3 31097 3 110558196
Total lung capacity decreased 19.27 12.97 16 31084 7098 110551101
Hand deformity 19.03 12.97 20 31080 218486 110339713
Neutropenia 18.89 12.97 49 31051 374571 110183628
Inflammatory pain 18.67 12.97 9 31091 1544 110556655
Bacterial vulvovaginitis 18.52 12.97 7 31093 661 110557538
Hypothalamic pituitary adrenal axis suppression 18.37 12.97 7 31093 675 110557524
Joint injury 18.32 12.97 37 31063 39957 110518242
Constipation 18.30 12.97 167 30933 357619 110200580
Blood pressure inadequately controlled 18.29 12.97 16 31084 7617 110550582
Cardiovascular disorder 18.27 12.97 27 31073 22733 110535466
Polydipsia 18.19 12.97 16 31084 7672 110550527
Poor quality sleep 17.95 12.97 30 31070 28047 110530152
Inappropriate schedule of product administration 17.82 12.97 108 30992 203529 110354670
Urinary tract infection 17.77 12.97 41 31059 326241 110231958
Mucosal inflammation 17.45 12.97 3 31097 96138 110462061
Cough 17.27 12.97 69 31031 461572 110096627
African trypanosomiasis 17.13 12.97 3 31097 10 110558189
Eczema herpeticum 16.83 12.97 6 31094 480 110557719
Oxygen saturation decreased 16.53 12.97 12 31088 156970 110401229
Central obesity 16.37 12.97 9 31091 2027 110556172
Asthenia 16.35 12.97 120 30980 688879 109869320
C-reactive protein abnormal 16.35 12.97 8 31092 129687 110428512
Chest discomfort 16.19 12.97 15 31085 173833 110384366
Leukopenia 16.16 12.97 11 31089 148780 110409419
Breath sounds abnormal 16.05 12.97 27 31073 25377 110532822
Rhabdomyolysis 15.84 12.97 7 31093 120394 110437805
Fatigue 15.76 12.97 244 30856 1215714 109342485
Gastrointestinal haemorrhage 15.74 12.97 14 31086 165504 110392695
Spontaneous ejaculation 15.70 12.97 3 31097 18 110558181
Skin swelling 15.58 12.97 15 31085 8065 110550134
Dermatophytosis of nail 15.32 12.97 5 31095 306 110557893
International normalised ratio increased 15.12 12.97 3 31097 86769 110471430
Electrocardiogram QT prolonged 14.87 12.97 6 31094 108954 110449245
Cell marker increased 14.86 12.97 6 31094 675 110557524
Duodenal ulcer perforation 14.66 12.97 17 31083 177683 110380516
Adrenal insufficiency 14.63 12.97 35 31065 42355 110515844
Lactic acidosis 14.61 12.97 4 31096 92807 110465392
Nail psoriasis 14.59 12.97 6 31094 708 110557491
Cutaneous T-cell lymphoma 14.47 12.97 10 31090 3374 110554825
Respiratory failure 14.37 12.97 24 31076 215308 110342891
Hypoxia 14.20 12.97 73 31027 129442 110428757
Metastases to central nervous system 14.08 12.97 24 31076 22793 110535406
Tachycardia paroxysmal 14.07 12.97 5 31095 396 110557803
Loss of personal independence in daily activities 14.05 12.97 81 31019 149939 110408260
Rheumatoid factor positive 13.94 12.97 10 31090 131630 110426569
Loss of consciousness 13.93 12.97 21 31079 196285 110361914
Puncture site erythema 13.92 12.97 3 31097 35 110558164
Disease progression 13.83 12.97 30 31070 244004 110314195
Metastases to lymph nodes 13.79 12.97 19 31081 15013 110543186
Encephalopathy 13.72 12.97 3 31097 81052 110477147
Suicide attempt 13.62 12.97 6 31094 103388 110454811
Movement disorder 13.59 12.97 31 31069 36373 110521826
Balance disorder 13.51 12.97 8 31092 116552 110441647
Pancytopenia 13.40 12.97 24 31076 209589 110348610
Cardio-respiratory arrest 13.35 12.97 8 31092 115828 110442371
Nightmare 13.31 12.97 32 31068 38831 110519368
Hepatic enzyme increased 13.28 12.97 46 31054 320846 110237353
Splenic granuloma 13.23 12.97 3 31097 45 110558154
Pericarditis 13.21 12.97 26 31074 219088 110339111
Hallucination 13.18 12.97 6 31094 101426 110456773
Shared psychotic disorder 13.16 12.97 3 31097 46 110558153
White blood cell count decreased 13.16 12.97 28 31072 229362 110328837
Skin plaque 13.16 12.97 17 31083 12628 110545571
Syncope 13.12 12.97 23 31077 202513 110355686
Skin lesion 13.09 12.97 38 31062 51593 110506606
Cushing's syndrome 13.06 12.97 6 31094 924 110557275
Therapeutic product effect decreased 13.06 12.97 31 31069 244285 110313914

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
CHEBI has role CHEBI:35472 anti-inflammatory drug
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35845 gout suppressant
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:49201 anti-ulcer drug
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:51177 antitussive
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:77715 nasal decongestant
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:233423 antifibrotic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tinea pedis indication 6020002 DOID:12403
Atopic dermatitis indication 24079001 DOID:3310
Contact dermatitis indication 40275004 DOID:2773
Seborrheic dermatitis indication 50563003 DOID:8741
Lichen simplex chronicus indication 53891004
Granuloma annulare indication 65508009 DOID:3777
Tinea corporis indication 84849002
Pruritus ani indication 90446007
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Tinea cruris indication 399029005
Primary cutaneous T-cell lymphoma indication 400122007
Psoriasis off-label use 9014002 DOID:8893
Congenital ichthyosis of skin contraindication 13059002
Hypervitaminosis D contraindication 27712000 DOID:9971
Guttate psoriasis contraindication 37042000
Hypercalcemia contraindication 66931009 DOID:12678
Disorder of calcium metabolism contraindication 71638002 DOID:10575
Hypercalciuria contraindication 71938000
Pustular psoriasis contraindication 200973000
Telangiectasia disorder contraindication 247479008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Pruritus associated with dermatoses Indication
Dogs Pruritus associated with dermatoses Indication
Horses Inflammatory joint conditions Indication

🐶 Veterinary products

ProductApplicantIngredients
Betasone Aqueous Suspension Intervet Inc. 2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.48 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 10179137 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 9364485 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 9433630 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 9439911 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 9655907 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 9775851 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 9877974 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL 10660908 June 10, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL 10688108 June 10, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL 9119781 June 10, 2031 PLAQUE PSORIASIS
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL 9119781 June 10, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
0.064%;0.005% WYNZORA MC2 N213422 July 20, 2020 RX CREAM TOPICAL 12440499 March 18, 2039 TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST CHEMBL CHEMBL
Glucocorticoid receptor Transcription factor IC50 8.28 CHEMBL

External reference:

IDSource
4018642 VUID
N0000179052 NUI
D01637 KEGG_DRUG
1514 RXNORM
C0053523 UMLSCUI
CHEMBL1200384 ChEMBL_ID
C011175 MESH_SUPPLEMENTAL_RECORD_UI
826Y60901U UNII
21800 PUBCHEM_CID
DB00443 DRUGBANK_ID
10006 MMSL
129 MMSL
31630 MMSL
3190 MMSL
4270 MMSL
4273 MMSL
d00628 MMSL
C0005308 UMLSCUI
9782 PUBCHEM_CID
1045 INN_ID
4018642 VANDF
4018644 VANDF
D001623 MESH_DESCRIPTOR_UI
002168 NDDF
002171 NDDF
116571008 SNOMEDCT_US
29896003 SNOMEDCT_US
88736007 SNOMEDCT_US
CHEBI:3077 CHEBI
826Y60901U INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0055 CREAM 0.50 mg TOPICAL NDA 18 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0056 OINTMENT 0.50 mg TOPICAL NDA 18 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0057 LOTION 0.50 mg TOPICAL ANDA 18 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0168-0258 CREAM 0.50 mg TOPICAL ANDA 27 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0267 LOTION, AUGMENTED 0.50 mg TOPICAL ANDA 27 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0268 OINTMENT, AUGMENTED 0.50 mg TOPICAL ANDA 27 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0472-0379 CREAM 0.50 mg TOPICAL ANDA 24 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0472-0379 CREAM 0.50 mg TOPICAL ANDA 24 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0380 CREAM 0.50 mg TOPICAL ANDA 10 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0381 OINTMENT 0.50 mg TOPICAL ANDA 10 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0382 OINTMENT, AUGMENTED 0.50 mg TOPICAL ANDA 24 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0659 CREAM 0.50 mg TOPICAL ANDA 10 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0807 LOTION 0.50 mg TOPICAL ANDA 11 sections
calcipotriene and betamethasone dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0713-0848 SUSPENSION 0.50 mg TOPICAL ANDA 25 sections
BETAMETHASONE DIPROPIONATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-032 CREAM 0.64 mg TOPICAL ANDA 18 sections
BETAMETHASONE CLOTRIMAZOLE HUMAN PRESCRIPTION DRUG LABEL 2 16590-033 CREAM 0.64 mg TOPICAL ANDA 12 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 16714-496 CREAM 0.50 mg TOPICAL ANDA 28 sections
Betamethasone dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 16714-996 CREAM 0.50 mg TOPICAL ANDA 16 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 21695-333 CREAM 0.64 mg TOPICAL ANDA 25 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 21695-521 CREAM 0.64 mg TOPICAL ANDA 19 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 21695-614 OINTMENT 0.05 mg TOPICAL ANDA 18 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 21922-104 LOTION, AUGMENTED 0.50 mg TOPICAL ANDA 25 sections
BETAMETHASONE DIPROPIONATE Human Prescription Drug Label 1 35573-107 OINTMENT, AUGMENTED 0.50 mg TOPICAL ANDA 24 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 45802-021 LOTION 0.50 mg TOPICAL ANDA 20 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 45802-021 LOTION 0.50 mg TOPICAL ANDA 20 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 45802-376 CREAM 0.50 mg TOPICAL ANDA 24 sections
BETAMETHASONE DIPROPIONATE HUMAN PRESCRIPTION DRUG LABEL 1 45802-505 OINTMENT 0.50 mg TOPICAL ANDA 18 sections
Calcipotriene and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 45802-816 OINTMENT 0.64 mg TOPICAL ANDA 25 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0235 CREAM 0.50 mg TOPICAL NDA 18 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0236 OINTMENT 0.50 mg TOPICAL NDA 19 sections